CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that William "Obi"
Greenman has been promoted to chief business officer. This position
capitalizes on his demonstrated leadership in achieving business goals
for INTERCEPT Blood System and guiding Cerus' corporate strategy.
"Obi's contributions to the development, commercialization, marketing
and sales of the INTERCEPT Blood System have been a critical element in
Cerus' success," said Claes Glassell, Cerus' president and chief
executive officer. "He brings a passion and depth of knowledge that we
expect will continue to drive the company forward as we grow our sales
in Europe, pursue new markets for INTERCEPT platelets and plasma, and
advance our INTERCEPT red cell program toward European approval."
Mr. Greenman has been Cerus' senior vice president, business development
and marketing since 2008. From 2006 to 2008, he held the position of
president, Cerus Europe, and prior to that, after returning to the
company from a brief time in the venture capital business, he served as
vice president, business development. Prior to joining Cerus in 1995 as
director of business development, Mr. Greenman worked in various
marketing and business development positions in Baxter's Biotech
Division from 1991 to 1995.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action allows
INTERCEPT treatment to inactivate both established transfusion threats,
such as hepatitis, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as influenza, malaria and dengue. Cerus
currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, Russia, the Middle East and selected
countries in other regions around the world. The INTERCEPT red blood
cell system is in clinical development. Visit http://www.cerus.com
for more information.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to the scope and rate
of sales of the INTERCEPT Blood System, the pursuit of new markets for
INTERCEPT platelets and plasma and European approval of the INTERCEPT
red cell program. Words such as "expect" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon the company's current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including,
without limitation, risks associated with commercial adoption of
INTERCEPT pathogen inactivation technology, regulatory approvals, as
well as other risks detailed in the Cerus' filings with, the Securities
and Exchange Commission (SEC), including in Cerus' quarterly report on
Form 10-Q for the quarter ended March 31, 2010, filed with the SEC on
May 12, 2010. No pathogen inactivation system has been shown to
inactivate all pathogens. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. Cerus does not undertake any obligation to
update any forward-looking statements as a result of new information,
future events, changed assumptions or otherwise.
Source: Cerus Corporation